Patient-Focused Drug Development: US FDA’s Guidance Development Effort Passes The Mid-Point
Executive Summary
Agency has issued two of four methodological draft guidances required under 21st Century Cures Act and convened workshops on the two documents still to come; industry, patient groups applaud FDA’s initiative but point to gaps in the guidance series, particularly around interactions with the agency on patient experience data and approaches to collecting patient preference information.
You may also be interested in...
Efforts Build For Global Approach To Patient-Focused Drug Development
The International Council for Harmonisation wants to ensure that methods used to collect and integrate patient views into drug development and regulatory decision-making follow agreed standards.
PDUFA VII Talks To Begin With COVID-19, Other Familiar Issues To Consider
US FDA staffing problems and patient engagement enhancements will be listed as priorities during reauthorization kick-off meeting.
Could ICER Outreach To US FDA Lead To Better Cost Effectiveness Analyses?
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: